Table 1.
Commercially available xMAP-based assay kits for nucleic acid detection
| Company | Application | Analyte(s) | Assay format | Features |
|---|---|---|---|---|
| Ambion Diagnostics (Austin, TX) | Genetic disease screening | Cystic fibrosis: 25 mutations, 6 polymorphisms | Direct hybridization | Homogeneous, Signature Script analysis software |
| Ashkenazi Carrier Panel: 23 mutations in 8 genes | ||||
| Marligen Biosciences, Inc. (Ijamsville, MD) | SNP genotyping | Y chromosome SNPs | Direct hybridization | Direct fluorescent labeling of PCR products |
| Mitochondrial DNA polymorphisms | ||||
| One Lambda, Inc. (Canoga Park, CA) | HLA DNA typing | HLA A, B, C; DRB1, DRB3,4,5; DQB1 | Direct hybridization | Internal positive and negative controls, approved for IVD use |
| Proactive Medical Technologies, Inc. (Austin, TX) | Infectious disease | Acute Respiratory Infection Panel: SARS-CoV, Influenza A and B, Parainfluenza 1 and 3, RSV | Direct hybridization with microsphere capture | Proprietary MDD™ technology |
| Tepnel Lifecodes (Stamford, CT) | HLA DNA typing | HLA A, B, C, DRB, DQB | Direct hybridization | Asymmetric PCR, homogeneous, internal positive control, CE marked for IVD in Europe |
| Tm Bioscience (Toronto, Ontario) | SNP genotyping | Cytochrome P450: CYP2C19, CYP2C9, CYP2D6 | ASPE with microsphere capture | Tag-It™ universal array platform |
| Genetic disease screening | Thrombophilia: Factor V, Factor II, MTHFR677, MTHFR1298 | |||
| Cystic fibrosis: 39 mutations, 4 polymorphisms; 40 mutations, 4 polymorphisms | ||||
| Ashkenazi Jewish Panel: 31 mutations and polymorphisms in 8 genes |